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Objective: To determine the clinical features associated with histologically proven rheumatoid vasculi-
tis (HRV) and the additional diagnostic value of serological markers in an inception cohort of 81
patients with rheumatoid arthritis (RA) suspected of RV.
Methods: The presence and number of recently developed extra-articular manifestations (EAMs) and a
weighted EAM score, as well as the levels of serological markers, were compared between 31 patients
with RA with histologically proven vasculitis and 50 patients with RA in whom vasculitis could not be
documented histologically. The following markers were evaluated: circulating immune complexes,
complement components C3 and C4, class-specific rheumatoid factors (IgM RF, IgG RF, IgA RF),
antineutrophil cytoplasmic antibodies, antinuclear antibodies, antiendothelial antibodies, circulating
intercellular adhesion molecule-1 and -3, circulating vascular cell adhesion molecule and E-selectin,
cellular fibronectin, von Willebrand factor antigen, and C reactive protein. The diagnostic value of
these markers, in addition to the clinical features, was evaluated with logistic regression analysis.
Results: Peripheral neuropathy or purpura/petechiae, or both, were the most important clinical
features to discriminate patients with RA with and without histologically proven RV. The presence of a
high number of EAMs and a higher weighted EAM score in patients with RA suspected of vasculitis
were also associated with an increased probability of histologically proven RV. After adjustment for
EAMs, only the combination of an increased serum IgA RF level and a decreased serum C3 level
appeared to make an additional contribution to the diagnosis histologically proven RV. Evidence of
systemic vasculitis was found in a muscle biopsy of the rectus femoris in 9/14 (64%) patients with vas-
culitis with neuropathy and in 3/11 (27%) patients with purpura/petechiae and vasculitis of the skin.
Conclusions: In the diagnostic process of RV the presence of peripheral neuropathy and/or purpura/
petechiae or a high weighted EAM score will increase the probability of histologically proven RV. Of
the circulating factors previously suggested to be markers for RV only IgA RF and C3 further increase
the probability of histologically proven RV and may be useful to guide diagnostic decisions.
Vasculitis in rheumatoid arthritis (RA) has a heterogene-ous clinical presentation. Neuropathy, rash, skin ulcers,gangrene, and abnormalities of visceral organs have
been described in association with rheumatoid vasculitis
(RV).1 2 In RV small and medium sized vessels can be affected,
which is histologically characterised by the presence of an
inflammatory infiltrate associated with destruction of the
vessel wall.3 The diagnosis RV is associated with a considerable
mortality 1 4–6 and may have important implications for patient
management.7 8 Therefore the diagnosis RV is generally
pursued by histological examination of a biopsy specimen of
affected organs or by muscle9 or rectum samples.10 The
availability of non-invasive blood tests that mark the presence
of vasculitis would be useful. Several serological markers have
been suggested for their usefulness in the diagnosis and man-
agement of RV. These include circulating immune
complexes,11 complement components,11 antiendothelial
antibodies,12 antineutrophil cytoplasmic antibodies,13 circulat-
ing adhesion molecules,14 and circulating cellular
fibronectin.15 Furthermore, raised levels of serum rheumatoid
factors (RFs) of different immunoglobulin classes16 and the
presence of antinuclear antibodies17 were reported in a high
proportion of patients with RV. In other forms of vasculitis von
Willebrand factor (vWF) antigen was proposed as a possible
disease marker.18 19
At present little is known about the optimal diagnostic
strategy to be pursued in patients with RA clinically suspected
of RV. This study on a cohort of patients with RA suspected of
RV aimed at answering the following questions: (a) Which
clinical symptoms or combinations of symptoms are associ-
ated with a high probability of histologically proven rheuma-
toid vasculitis (HRV)? (b) What is the additional diagnostic
value of serological markers in patients with clinical suspicion
of HRV?
PATIENTS AND METHODS
Patients
Consecutive patients (n=81) with RA and recent onset (<6
months) of extra-articular manifestations (EAMs) who
attended the Department of Rheumatology between June
1993 and August 1996 were enrolled in a diagnostic study on
the assessment of vasculitis. The following EAMs were
considered to be related to RV unless their presence could be
explained otherwise: non-compressive peripheral neuropathy
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(mononeuritis multiplex, distal symmetric sensory or sensori-
motor neuropathy (DSSN)), deep and superficial skin ulcers,
gangrene, necrotising glomerulonephritis, fibrosing alveolitis,
ischaemic colitis, skin rash, pulp lesions, nailfold lesions, peri-
carditis, pleuritis, (epi-)scleritis, scleromalacia perforans,
weight loss (>10% in six months), fever, and multiple
rheumatoid nodules. All patients with EAMs were extensively
investigated for RV following a predefined protocol. This
included histological examination of a full thickness (skin/
muscle/fascia) biopsy specimen of the rectus femoris muscle
in all patients and a biopsy sample of the tibial muscle in those
patients who were willing to participate in a substudy on the
value of such a biopsy procedure. The former muscle biopsy
was obtained by an open surgical procedure, whereas the lat-
ter muscle biopsy was obtained with a forceps.20 The size of the
sample obtained was ±1×1×1 cm for the rectus femoris muscle
and ±0.5×0.5×0.5 cm for the tibial muscle. If no vasculitis was
seen in either muscle biopsy, a sural nerve biopsy was done in
patients with peripheral neuropathy, confirmed by electro-
myographic abnormalities of the sural nerve. Furthermore, a
skin biopsy was performed in all patients with skin rash—that
is, petechiae or purpura or rash, but not of skin ulcers. Vascu-
litis was defined as the observation of fibrinoid necrosis in a
vessel wall within a muscle or sural nerve biopsy, or of leuco-
cytoclasis in a skin biopsy. No immunofluorescent analysis on
tissue was done. A large number of sections (n=45) from each
muscle biopsy were examined to avoid, as far as possible, false
negative test results due to discontinuous distribution of the
lesions.21 Patients with EAMs were classified as HRV or
RA+EAM according to, respectively, the presence or absence
of histological evidence of vasculitis in any tissue biopsy. Thus,
31/81 patients with RA suspected of vasculitis were classified
as HRV and 50 patients as RA+EAM.
Controls for the laboratory parameters included 44 con-
secutive patients with RA without clinical suspicion of vascu-
litis (RA−). These control patients attended the clinic between
August 1995 and August 1996 and were matched for age, sex,
disease duration, and clinic referral status of the patients with
HRV and RA+EAM. The RA− control patients showed no sign
of the above mentioned EAMs within six months before blood
sampling or after at least six months of follow up. No
histological diagnostic procedure was performed in these
patients.
All patients fulfilled the criteria of the American College of
Rheumatology for RA.22
Blood samples
Blood samples were obtained at the time of enrolment in the
study and before biopsies were performed in patients with
HRV and RA+EAM. For the assessment of the vWF antigen
venous blood was collected in 1/10 volume of 0.11M trisodium
citrate and centrifuged at 2500 g for 20 minutes. Serum and
plasma samples were obtained simultaneously and were
stored at, respectively, −20° and −80°C until use.
Laboratory parameters
In serum samples, levels of circulating immune complexes
(CICs) were measured by a C1q binding assay.23 Levels of com-
plement components C3 and C4 were measured as previously
described.24 The normal ranges are: CICs 0 µgEq/ml of aggre-
gated IgG, C3 0.7–1.0 g/l, C4 0.2–0.3 g/l. Enzyme linked
immunosorbent assays (ELISAs) were used to determine lev-
els of antiendothelial antibodies (AEA),25 circulating intercel-
lular adhesion molecule (ICAM)-1 and -3, circulating vascular
cell adhesion molecule (VCAM), and E-selectin,26 as well as
cellular fibronectin (cFN).15 Normal ranges are: AEA 0 U/ml,
ICAM-1 115–306 ng/ml, ICAM-3 15–37 ng/ml, VCAM 395–714
ng/ml, E-selectin 29–63 ng/ml, cFN <208% of pooled normal
plasma. Antineutrophil cytoplasmic antibodies (ANCA) were
determined as described13 and included indirect immuno-
fluorescence, ELISA for the levels of antibodies against protei-
nase 3 (PR3), myeloperoxidase (MPO), and lactoferrin (LF).
Normal values are: anti-PR3 <8.0 U/ml, anti-MPO <31.6
U/ml, anti-LF <50.1 U/ml. Levels of class-specific rheumatoid
factors were measured by an ELISA.27 Normal values are: IgM
RF <5 U/ml, IgG RF <200 U/ml, IgA RF <4 U/ml. Determina-
tions of antinuclear antibodies (ANA) were performed by
indirect immunofluorescence on cultured Hep-2 cells. The
presence or absence of cryoglobulins was determined. In
plasma samples, levels of vWF antigen were determined by
ELISA.28 The normal range is 0.36–2.15 IU/ml.
Statistical analysis
Clinical features
Differences in demographic and disease characteristics, as
well as the presence and number of EAMs between patients
with HRV and RA+EAM were tested by χ2 test or Mann-
Whitney U test, where appropriate.
The association of EAMswith HRVwas determined for each
EAM separately and for combinations of EAMs, using logistic
regression analysis and expressed as odds ratios with 95%
confidence intervals. Subsequently, all EAMs were entered in
a logistic regression model to evaluate which of the entry
variables were independently associated with HRV.
Furthermore, the association between HRV and the number
of EAMs, as well as a weighted EAM score, was determined.
The term weighted EAM score represents the clinical
suspicion for RV which depends on the type of EAM seen in a
patient. Based on the consensus judgment of clinicians and
information from published reports, each EAM was given a
score ranging from 1 to 4, a score of 4 representing the highest
suspicion of RV. The weighted EAM score was calculated by
adding up the scores of each EAM seen in one patient. The
following score was given to the EAMs: peripheral neuropathy,
deep skin ulcers, gangrene, necrotising glomerulonephritis,
fibrosing alveolitis, and ischaemic colitis were each given a
score of 4; skin rash a score of 3; nailfold lesions, scleromala-
cia perforans, (epi-)scleritis, and superficial skin ulcers a score
Table 1 Demographic and disease characteristics of
81 patients with recent onset of extra-articular
manifestations and a suspicion of rheumatoid vasculitis
HRV (n=31)
RA+EAM
(n=50)
RA−
(n=44)
Age, years (range) 70 (49–85) 66 (38–85) 65
(38–84)
Female (No (%)) 18 (58) 29 (58) 26 (59)
RA disease duration, years
(range)
14 (1–52) 13 (0–44) 10
(0–33)
Patients with (%)
Nodules (previous onset) 74 60 18
RF 100 96 96
Joint erosions 97 98 91
Arthritis activity (range)
Swollen joint count 8 (0–16) 7 (0–15) ND
Painful joint count 8 (0–24) 8 (0–35) ND
Treatment (%)
Corticosteroids 32 28 NA
Methotrexate 10 18 NA
Others 49 42 NA
None 16 8 NA
Vasculitis observed in (n)
Muscle 17/31 0/50 ND
Skin 9/11 0/3 ND
Muscle and skin 3/3 ND
Sural nerve 2/2 0/6 ND
HRV, histologically proven rheumatoid vasculitis and recent onset of
extra-articular manifestations; RA+EAM, rheumatoid arthritis with
recent onset of extra-articular manifestations, but without histological
evidence of vasculitis; RA−, rheumatoid arthritis, without recent onset
of extra-articular manifestations or a suspicion of vasculitis; RF,
increased levels of serum rheumatoid factor, measured at any time
during the disease course of RA.
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of 2; weight loss, fever, pericarditis, pleuritis, and multiple
rheumatoid nodules a score of 1. The weighted EAM score
could reach a maximum score of 40. The weighted EAM score
was constructed by the authors before the study design.
The sensitivity, specificity, accuracy, and predictive values of
the EAMs, number of EAMs, and the weighted EAM score
were calculated.Accuracy is defined as the percentage patients
correctly classified as either HRV or RA+EAM. To determine
the diagnostic value of non-dichotomous variables the
optimal cut off point was estimated by receiver operating
characteristic (ROC) curves.
Laboratory parameters
Differences in serum or plasma levels of laboratory parameters
of patients with HRV, RA+EAM and RA− controls were tested
by χ2 test or Mann-Whitney U test, where appropriate. In
addition, laboratory parameters were dichotomised. Thresh-
olds were determined such that 95% of the RA control group
was normal. The laboratory parameters which were found to
differ between HRV and RA+EAM at a p value <0.10 were
selected for further evaluation.
The strength of association between HRV and selected labo-
ratory parameters was determined univariately by logistic
regression analysis, expressed as odds ratios with 95%
confidence interval. Subsequently, to evaluate the additional
diagnostic value of laboratory parameters above that of clini-
cal symptoms, the strength of association between HRV and
each selected laboratory parameter was adjusted for the
weighted EAM score. Finally, to evaluate which of the selected
laboratory parameters were independently associated with
HRV, a stepwise logistic regression analysis was done on all
selected laboratory parameters adjusted for the weighted
EAM score.
RESULTS
Clinical features
In total, 31/81 (38%) patients were found to have vasculitis in
any of the biopsy samples taken. In the 81 patients suspected
of RV, vasculitis was found on histological examination of the
rectus femoris muscle (17/81 (21%)), tibial muscle (10/77
(13%)), skin (12/17 (71%)), and sural nerve (2/8 (25%)). Both
rectus femoris and tibial muscle were sampled in 27/31
patients with HRV. Of those 27 patients with HRV, vasculitis
was found in both muscle biopsies in seven patients with HRV
(26%), only in the rectus femoris muscle in six patients with
HRV (22%), only in the tibial muscle in three patients with
HRV (11%), and in neither muscle biopsies in 11 patients with
HRV (41%).
Demographic and disease characteristics of HRV, RA+EAM,
and RA− control patient groups did not differ significantly,
except for a longer median disease duration and a higher pro-
portion of nodules in patients with HRV than in RA− control
patients (table 1).
Table 2 presents the EAMs occurring in the preceding six
months that motivated the diagnostic procedure for RV. The
most common were the presence of weight loss, nailfold
lesions, purpura/petechiae, peripheral neuropathy (in particu-
lar, DSSN), and skin ulcers. The EAMs most strongly
associated with RV were petechiae/purpura and DSSN (table
2). Of 14 patients with HRV with peripheral neuropathy, two
had peripheral neuropathy only and 12 patients had
additional features: gangrene (n=1), deep skin ulcer (n=2),
purpura/petechiae (n=3), scleromalacia perforans (n=1),
weight loss (n=7), fever (n=2), nailfold lesions (n=7), super-
ficial skin ulcer (n=1), pleuritis (n=1), and multiple rheuma-
toid nodules (n=2). Of the 14 patients with HRV with periph-
eral neuropathy, nine (64%) had vasculitis in a rectus femoris
muscle biopsy, an additional two only in the tibial muscle
biopsy, and an additional two only in a sural nerve biopsy. Of
the 11 patients with HRV with purpura/petechiae but no neu-
ropathy, six had purpura/petechiae only, and five had purpura/
petechiae with additional features: deep skin ulcer (n=1),
weight loss (n=1), fever (n=1), nailfold (n=3), episcleritis
(n=1). Of the 11 patients with HRV with purpura/petechiae
but no peripheral neuropathy, 10 had vasculitis in a skin
biopsy, and three (27%) had vasculitis in a rectus femoris
Table 2 Extra-articular manifestations (EAMs) of recent onset in 81 patients
suspected of rheumatoid vasculitis and associations between EAMs and histologically
proven rheumatoid vasculitis. Results are shown as No (%)
HRV (n=31) RA+EAM (n=50)
Odds ratio* (95%
confidence interval)
Peripheral neuropathy 14 (45)† 6 (12) 6.04 (1.9 to 18.9)
Mononeuritis multiplex 3 (10) – ∞
DSSN 14 (45) 6 (12) 6.04 (1.9 to 18.9)
Skin 25 (81) 29 (58) 3.02 (1.0 to 8.8)
Ulcers 7 (23) 11 (22) 1.03 (0.3 to 3.1)
Deep skin ulcer 3 (10) 2 (4) 2.56 (0.4 to 16.8)
Superficial skin ulcer 4 (13) 9 (18) 0.68 (0.2 to 2.5)
Gangrene 1 (3) 1 (2) 1.63 (0.1 to 28.5)
Purpura/petechiae 14 (45) 3 (6) 12.94 (3.2 to 52.5)
Nailfold lesions 14 (45) 21 (42) 1.14 (0.5 to 2.9)
Systemic features (weight loss+ fever) 14 (45) 24 (48) 1.65 (0.2 to 12.9)
Weight loss 13 (42) 19 (38) 1.17 (0.5 to 3.0)
Fever 3 (10) 7 (14) 0.66 (0.2 to 2.8)
Eye involvement 5 (16) 4 (8) 2.21 (0.5 to 9.2)
Scleromalacia perforans 1 (3) 1 (2) 1.63 (0.19 to 28.5)
(Epi-)scleritis 4 (13) 3 (6) 2.32 (0.5 to 11.5)
Pericarditis 0 1 (2) 0 (–)
Pleuritis 2 (6) 6 (12) 0.51 (0.1 to 2.3)
Fibrosing alveolitis 1 (3) 1 (2) 1.63 (0.1 to 28.5)
Multiple rheumatoid nodules (recent onset) 2 (6) 4 (8) 0.79 (0.1 to 4.8)
HRV, histologically proven rheumatoid vasculitis and recent onset of extra-articular manifestations; RA+EAM,
rheumatoid arthritis with recent onset of extra-articular manifestations, but without histological evidence of
vasculitis; DSSN, distal symmetric sensory or sensorimotor neuropathy.
*Association of EAM with RV; †number of patients (%);
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muscle biopsy. The remaining six patients with HRV, who had
no peripheral neuropathy or purpura/petechiae, presented a
combination of any of the following features: weight loss
(n=5), nailfold lesions (n=4), superficial skin ulcer (n=3),
pleuritis (n=1), or episcleritis (n=2). In these latter six
patients, vasculitis was seen in a rectus femoris muscle biopsy.
The number of EAMs (mean 2.5, range 1–7) in the patients
with HRV was significantly higher (p<0.01) than that in the
patients with RA+EAM (mean 1.7, range 1–3). The weighted
EAM score was also significantly (p<0.0001) higher in
patients with HRV (mean 5.9, range 3–15) than that in
patients with RA+EAM (mean 3.0, range 1–8). Table 3
presents the diagnostic value of each EAM of interest in
patients suspected of RV (that is, patients with HRV and
RA+EAM). As shown, the presence of skin rash (purpura/
petechiae) or neuropathy increases the probability of the pres-
ence of HRV from 38% among the total study group to 82%
among those patients with skin rash or neuropathy. The high-
est accuracy was found for a combination of peripheral
neuropathy and purpura/petechiae. The accuracy of the
number of EAMs and the weighted EAM score was found to
be the highest at a optimal cut off point of >4 EAMs and at a
weighted EAM score>6, respectively. The association between
HRV and the EAMs, expressed as odds ratios, at the optimal
cut off points was 3.79 (95% confidence interval (CI) 1.3 to
10.7) for the number of EAMs (<2 v>3) and 7.41 (95% CI 2.3
to 24.1) for the weighted EAM score (<5 v >6).
To evaluate which of the EAMs were independently associ-
ated with HRV, a stepwise logistic regression analysis was
done. Peripheral neuropathy and purpura/petechiae were
found to be the only EAMs that best explained the presence or
absence of HRV; the odds ratios for peripheral neuropathy and
Table 3 Diagnostic characteristics of extra-articular manifestations (EAMs) for
histologically proven rheumatoid vasculitis in 81 patients suspected of rheumatoid
vasculitis
Sensitivity Specificity Accuracy PPV NPV
EAM
Peripheral neuropathy 45 88 72 70 72
Purpura/petechiae 45 94 75 82 73
Peripheral neuropathy or purpura/petechiae 81 84 83 76 88
Number of EAM
>1 100 0 38 38 –
>2 77 46 58 47 77
>3 42 84 68 62 70
>4 23 100 70 100 68
Weighted EAM score*
>3 100 50 56 55 100
>5 58 80 72 64 76
>6 45 90 73 74 73
>9 19 100 69 100 67
Accuracy, percentage patients correctly classified as either HRV or RA+EAM; PPV, positive predictive value;
NPV, negative predictive value.
*Weighted EAM score; for explanation see “Patients and methods”.
Table 4 Laboratory variables measured in patients with rheumatoid vasculitis (HRV)
and in patients with rheumatoid arthritis with EAMs, but no histological evidence of
vasculitis (RA+EAM). Results are shown as No (%)
HRV( n=31) RA+EAM (n=50) Odds ratio (95 CI) p Value
CICs >52 µgEq/ml 16 (55) 11 (22) 4.3 (1.6 to 11.5) 0.006
C3 <0.7 g/l 19 (66) 9 (18) 8.4 (2.9 to 24.2) <0.0001
C4 <0.2 g/l 10 (35) 12 (25) 1.6 (0.6 to 4.4) 0.44
vWF >3.75 IU/ml 8 (35) 1 (2) 22.4 (2.6 to 194) 0.001
AEA >33 U/ml 7 (26) 13 (26) 1.0 (0.3 to 2.9) 0.99
ANCA
Cytoplasmatic 0 1 (2) – 0.99
Perinuclear 13 (48) 15 (30) 2.1 (0.8 to 5.5) 0.21
Non-specific 0 0 – –
Absent 14 (52) 34 (68) 1.0 (–) 0.21
Anti-PR3 >0.8 U/ml 1 (4) 2 (4) 0.9 (0.1 to 11.7) 0.99
Anti-MPO >30 U/ml 3 (11) 4 (8) 1.4 (0.3 to 7.0) 0.69
Antilactoferrin >25 U/ml 2 (7) 3 (6) 1.3 (0.2 to 8.0) 0.99
ICAM-1 >720 ng/ml 0 (0) 1 (2) 0 (–) 0.99
ICAM-3 >90 ng/ml 15 (54) 35 (71) 0.5 (0.2 to 1.2) 0.14
VCAM >1200 ng/ml 8 (29) 8 (16) 2.1 (0.7 to 6.3) 0.25
E-selectin >115 ng/ml 5 (18) 17 (35) 0.4 (0.1 to 1.3) 0.19
Cellular fibronectin >400% 18 (62) 13 (26) 4.7 (1.7 to 12.4) 0.002
IgM RF >265 U/ml 11 (37) 9 (18) 2.6 (0.9 to 7.4) 0.10
IgG RF >550 U/ml 13 (43) 7 (14) 4.7 (1.6 to 13.8) 0.007
IgA RF >14 U/ml 19 (63) 10 (20) 6.9 (2.5 to 19.1) <0.0001
ANA positive 13 (42) 20 (40) 1.1 (0.5 to 2.9) 0.82
ESR >59 mm/1st h 26 (84) 27 (54) 4.4 (1.5 to 13.4) 0.008
CRP >104.5 mg/l 2 (7) 10 (20) 0.3 (0.1 to 1.5) 0.19
Where appropriate, thresholds were determined such that 95% of the “RA−” control group was normal,
except for C3, IgA RF, and ESR. For these parameters thresholds were determined by ROC analysis of the
“HRV” versus “RA+EAM” groups.
*p Value of Fisher’s exact test.
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purpura/petechiae were 10.24 (95% CI 2.8 to 37.5) and 20.86
(95% CI 4.6 to 95.4), respectively. When all other possible
combinations of EAM were examined, no significant interac-
tion was found. The strengths of association of combinations
of EAMs with HRV were similar to the strength of association
of the separate EAMs with HRV as found by univariate analy-
sis.
Laboratory parameters
Serum or plasma levels of CICs, vWF, ICAM-3, VCAM,
E-selectin, cFN, IgM RF, IgG RF, IgA RF, and erythrocyte sedi-
mentation rate (ESR) were significantly higher in patients
with HRV than in RA− control patients. Serum levels of C3 and
C4 were significantly lower in patients with HRV than in the
control RA− patients. Between HRV and the control RA−
patients, no significant differences were found in the median
serum levels of AEA, anti-PR3, anti-MPO, anti-LF, ICAM-1,
CRP and in the presence of ANA or ANCA. When compared
with patients with RA+EAM, the serum or plasma levels of
CICs, vWF, cFN, IgM RF, and IgA RF were significantly higher
in patients with HRV. The serum levels of C3 were significantly
lower in patients with HRV than in patients with RA+EAM.
Between HRV and RA+EAM patients, no significant differ-
ences were found in serum levels of C4, AEA, anti-PR3,
anti-MPO, anti-LF, ICAM-1, ICAM-3, E-selectin, IgG RF, ESR,
CRP and in the presence of ANA or the ANCA pattern on
immunofluorescence. Cryoglobulins were not found in any of
the patients studied. Table 4 shows the laboratory parameters
as measured in patients with HRV and RA+EAM, in which the
laboratory parameters were dichotomised. Thresholds were
determined such that 95% of the RA control group was
normal, except for C3, IgA RF and ESR. For these parameters
thresholds were determined by ROC analysis of the HRV ver-
sus RA+EAM groups. Significant differences between HRV
and RA+EAMwere found for CICs, C3, vWF, cFN, IgG RF, IgA
RF, and ESR.
Diagnostic value of laboratory parameters in addition
to the clinical features
Table 5 shows the associations between HRV and selected
laboratory parameters, unadjusted and adjusted for the
weighted EAM score. Statistically significant associations with
HRV were found for increased serum CIC levels, decreased
serum C3 levels, increased plasma vWF levels, increased
serum cFN levels, increased serum levels of IgG RF, IgA RF,
and ESR. After adjustment for the weighted EAM score, CIC,
C3, vWF, IgA RF, and IgG RF were still significantly associated
with HRV (table 5). Entering all selected laboratory variables
and the weighted EAM score simultaneously, only IgA RF and
C3were still significantly associated with HRV,with a trend for
vWF (data not shown). Given a weighted EAM score, the
additional diagnostic value of measuring both IgA RF and C3
levels is higher than the additional value of measuring IgA RF
levels only. For instance, if only IgA RF were measured and
found to be increased (>14 IU/ml = median value of patients
with HRV and RA+EAM), at a pretest risk of 50% the post-test
probability for HRV was 66%. If both an increased IgA RF level
and a decreased C3 level (<0.7 g/l = median value of patients
with HRV and RA+ EAM) were found, the post-test probabil-
ity for HRV was 78%. Figure 1 illustrates the relation between
the pretest probability of HRV (on the x axis), as calculated
with the weighted EAM score, and the post-test probability of
HRV (on the y axis) after measuring IgA RF and C3 levels.
DISCUSSION
This study determines the diagnostic value of EAM and sero-
logical markers for histologically proven RV (HRV) in an
inception cohort of patients with RA clinically suspected of
vasculitis. The presence of peripheral neuropathy or skin rash
(purpura/ petechiae) increases the probability of HRV from
38% to 82%. The probability of HRV also increased consider-
ably with an increasing number of EAM present or with an
Table 5 Association between the diagnosis histologically proven rheumatoid
vasculitis and selected laboratory variables, presented as univariate crude odds ratios
and adjusted odds ratios, adjusted for the weighed EAM score
Crude Adjusted for weighed EAM score
Odds ratio (95% CI) p Value Odds ratio (95% CI) p Value
CIC >52 µgEq/ml 4.3 (1.6 to 11.5) 0.006 3.7 (1.2 to 11.8) 0.024
C3 <0.7 g/l 8.4 (2.9 to 24.2) <0.0001 7.3 (2.2 to 24.2) 0.001
vWF >3.75 IU/ml 22.4 (2.6 to 194) 0.001 11.9 (1.2 to 116) 0.033
Cellular fibronectin >400% 4.7 (1.7 to 12.4) 0.002 2.8 (0.9 to 8.3) 0.11
IgM RF >265 U/ml 2.6 (0.9 to 7.4) 0.11 1.3 (0.4 to 4.7) 0.66
IgG RF >550 U/ml 4.7 (1.6 to 13.8) 0.007 3.6 (1.1 to 12.4) 0.038
IgA RF >14 U/ml 6.9 (2.5 to 19.1) <0.0001 5.5 (1.7 to 17.9) 0.004
ESR >59 mm/1st h 4.4 (1.5 to 13.4) 0.008 2.1 (0.6 to 7.2) 0.23
Figure 1 Relation between the pretest probability of HRV (on the x
axis), as calculated with the weighted EAM score, and the post-test
probability of HRV (on the y axis) after measuring IgA RF and C3
levels. Increased IgA RF levels were defined as >14 U/ml. Normal
IgA RF levels were defined as <14 U/ml. C3 levels were decreased
if <0.7 g/l and normal if >0.7 g/l.
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increasing weighted EAM score. Of the serological markers
tested, only IgA RF and C3 appeared to make an additional
contribution to the probability of HRV.
In contrast with previous studies, this study used histology
as a “gold standard” for RV. The results show that the various
EAMs differ in their predictive value for the presence of HRV.
The strong association of peripheral neuropathy and/or skin
rash with HRV is in line with the findings of previous
studies.1 4 29 Mononeuritis multiplex had always been found in
association with vasculitis. In contrast with previous
observations,1 29 no relevant association was found between
HRV and nailfold lesions in combination with serositis or
(epi-)scleritis.
The question may be raised whether patients have subclini-
cal vasculitis and the gold standard used in this study is
adequate. Firstly, in our opinion histological vasculitis is prob-
ably always associated with clinical signs of vasculitis as all
our patients with HRV had EAMs of recent onset, and
histological evidence of vasculitis could not be found in any
patient with RA without extra-articular manifestations.9 To
minimise the possibility of misclassification an extensive his-
tological procedure was performed, with at least one muscle
biopsy (the majority had twomuscle biopsies) and if indicated
with skin or sural nerve biopsy. Furthermore, none of the
patients with RA+EAM developed progressive signs of vascu-
litis by at least one year after the diagnostic procedure. We
therefore think that the gold standard used in this study was
adequate.
The predictive value of the weighted EAM score for the
presence of HRV was no better than the presence of
neuropathy and/or skin rash. Nevertheless, this score, which
was based on clinical experience and designed before the
study, seemed to be remarkably accurate. The possible useful-
ness of such a score is suggested by the fact that not all
patients with HRV present peripheral neuropathy and/or skin
rash, though further validation of such a score seems
appropriate.
The additional diagnostic value of serological markers of
HRV was disappointing. All investigated serological tests have
been previously reported as markers for RV. In this study,
changed levels of CICs, C3, C4, von Willebrand factor antigen,
ICAM-3, VCAM, E-selectin, cFN, IgM RF, IgG RF, IgA RF, and
ESR were significantly different between patients with HRV
and RA controls. However, when diagnostically used in
patients with RA suspected of RV, only the changes in levels of
CIC, C3, vWF antigen, cFN, IgG RF, IgA RF, and ESR were still
significantly associated with HRV. Discrepancies between this
study and previous studies may be explained by differences in
the definition of the RV and RA control groups. The absence of
antiendothelial antibodies and antilactoferrin antibodies con-
trasts with the results of previous studies and remains
unexplained.12 13 The differences in CICs, vWF antigen, cFN,
IgM RF, and IgG RF between patients with RA, with and
without HRV, are of interest for an understanding of the
pathogenesis of RV, but have no additional value for the diag-
nostic process of RV.
Of the circulating factors previously suggested to be mark-
ers of RV, only increased IgA RF and decreased C3 levels
increase the probability of HRV in addition to the readily
available clinical information.Measurement of IgA RF and C3
was found to be of diagnostic value in all subgroups of
patients with RA suspected of RV—for example, patients with
recent onset of EAMs but no skin rash or neuropathy (data not
shown). The present results confirm previously reported
observations of increased serum IgA RF in patients with RV
compared with patients with RA without vasculitis.16 The role
of circulating IgA RF and C3 in the pathogenesis of RV is sug-
gested by the high prevalence of IgA immune complex depos-
its in combination with C3 deposits in the affected skin of
patients with HRV and the absence of such deposits in the skin
of patients with RA without vasculitis.30
Histological confirmation of RV should be directed to an
affected organ (skin or nerve), but the observation of vasculi-
tis in medium sized arteries in muscle or rectum is also
important. Previous observations suggest that patients with
vasculitis in the rectum or muscle have a worse outcome than
those with vasculitis limited to the skin only.10 31 There are two
reasons why we prefer a muscle biopsy. Firstly, a muscle biopsy
is easy to perform and less invasive than a rectum biopsy and,
secondly, the diagnostic yield is similar to a sural nerve biopsy
in patients with RV with peripheral neuropathy.5 Of the
patients whowere biopsied in twomuscles, vasculitis was seen
in 48% of the rectus femoris muscle biopsy specimens and in
37% of the tibial muscle biopsy specimens. The tibial muscle
biopsy obtained by forceps is easy to perform in a regular out-
patient clinic20 and less invasive than an open surgical biopsy
of the rectus femoris muscle. Although the investigation of the
diagnostic yield of the various invasive procedures was not the
primary aim of this study, the results suggests that a tibial
muscle biopsy obtained by a forceps is the best first step for the
documentation of vasculitis, particularly in patients without
skin rash. If no vasculitis is seen in a tibial muscle biopsy than
a biopsy of the rectus femoris muscle can be done.
One may argue whether in clinical practice RV can be diag-
nosed only on the basis of clinical signs or whether histologi-
cal confirmation is necessary. The clinical signs of RV are
heterogeneous and mostly non-specific, in particular when
these appear as an isolated feature, excepted for mononeuritis
multiplex which is diagnostic of RV. The differential diagnosis
of several features of RV is extensive, as has been reported for
skin ulcers32 and polyneuropathy,33 but also for other
features—for example, skin rash, weight loss, and fever. To
obtain a proper and prompt diagnosis and to have additional
support to initiate aggressive immunosuppressive treatment,
histological conformation of the diagnosis RV is advocated. It
is important to start aggressive immunosuppressive treatment
quickly because the survival of patients with RV with severe
organ lesions (neuropathy) who are treated promptly with
immunosuppressive drugs—that is, high dose corticosteroids
in combination with cyclophosphamide or azathioprine,
seems better than survival in those patients who are not
treated in this way.34 35 Likewise, patients with RV with other
severe organ lesions—for example, deep skin ulcers, might be
considered as having a poor prognosis and aggressive
immunosuppressive treatment could be started. However,
patients with RV with non-severe superficial skin lesions—for
example, purpura/petechiae or superficial skin ulcers, do not
have a poor prognosis and a change of disease modifying
antirheumatic drug (DMARD) treatment may be sufficient for
these patients, instead of treating them with aggressive
immunosuppressive drugs.31 Three of our patients with RV had
a rash as the only clinical manifestation in combination with
vasculitis in the skin biopsy and, interestingly, also in a mus-
cle biopsy. This observation suggests that some patients with
skin rash apparently may have systemic vasculitis. It has been
found that patients with systemic vasculitis in a biopsy have a
worse prognosis,1 which suggests that aggressive treatment
should be considered in patients with RV with rash and
systemic vasculitis in a muscle biopsy. For patients with RA
with EAMs but without HRV—that is, RA+EAM, vasculitis
only limited to a small part of an organ cannot be ruled out,
such as in nailfold lesions, episcleritis, pericarditis, pleuritis.
The prognosis of patients with RA with such lesions is gener-
ally good36 and adequate treatment with DMARDS or low dose
corticosteroids is probably sufficient.
In conclusion, the results of this study confirm that the
development of EAMs, particularly the presence of peripheral
neuropathy and skin rash, in RA increases the probability of
HRV. The study further demonstrates that serum IgA RF and
C3 levels in patients with RA are the only markers for HRV
that add to the diagnostic information obtained by careful
physical examination.
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